Brief: Fusion Pharma Nominates First Targeted Alpha Therapy Candidate In Collaboration With Astrazeneca For Ind-Enabling Studies
10/01/2022 22:14
Jan 10 (Reuters) - AstraZeneca PLC AZN.L :
* FUSION PHARMACEUTICALS ANNOUNCES NOMINATION OF FIRST
TARGETED
ALPHA THERAPY CANDIDATE IN COLLABORATION WITH ASTRAZENECA TO
ADVANCE INTO IND-ENABLING STUDIES FOR PHASE 1 DEVELOPMENT
* FUSION PHARMACEUTICALS INC - CO, ASTRAZENECA WILL SHARE
COSTS
EQUALLY THROUGH CLINICAL DEVELOPMENT
* FUSION PHARMACEUTICALS INC - IND ENABLING STUDIES ARE
ONGOING
Source text for Eikon: ID:nCNWRxZRba
Further company coverage: AZN.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusion Pharmaceuticals
See all newsBrief: Acquisition Of Fusion Pharmaceuticals Completed
Brief: Fusion Pharmaceuticals Receives Final Court Order Approving Arrangement
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Brief: Fusion Pharmaceuticals Shareholders Approve Acquisition By Astrazeneca
Fusion Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary